Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 November 2012: Clinical Research  

Short-term outcomes of en bloc resection of solitary bone metastases in limbs

Qingcheng Yang ABE , Bizeng Zhao AE , Zhichang Zhang C , Yang Dong D , Yao Pan ACF , Xinhui Du DE

DOI: 10.12659/MSM.883542

Med Sci Monit 2012; 18(11): CR648-655

0 Comments

Background

Metastatic cancer is usually found in the bone, which is the third most common site of cancer metastasis [1]. Metastatic bone cancer often occurs in the axial skeleton such as pelvis, ribs, skull, and vertebrae [2]. Metastatic cancer of the limbs is frequently found at the proximal end of long bones such as the proximal end of the humerus and femurs [3]. Metastatic cancer of the limbs inevitably causes pain, limb dysfunction and formation of a bump, or even results in pathological fracture. These complications significantly influence the quality of life (QOL) and affect the performance of adjunctive therapies, including chemotherapy and radiotherapy, which may further influence the survival time and the prognosis of these patients [4–6].

Non-surgical treatment is a major strategy for the treatment of multiple metastatic bone cancers of limbs, and, in addition to radiation (external beam radiation, radiopharmaceuticals), adjunctive therapies include bisphosphonates and chemotherapeutic agents, ablative techniques (radiofrequency ablation [RFA] and cryoablation), inhibitors of RANK-RANKL interaction (eg, denosumab), hormonal therapies, and interventional techniques (eg, kyphoplasty) [7,8]. For patients developing pathological fracture at the limbs, palliative surgical treatment is frequently adopted in which the lesions are removed completely, followed by filling of bone cement and fixation with plates and screws or intramedullary nails [9–11]. These treatments may relieve the pain, but are less beneficial for the recovery of limb function, and weight-bearing walking is usually not possible using a crutch or a walker, so these patients often have poor QOL [12–14]. For patients with solitary metastatic bone cancer of the limbs, palliative surgical treatment is often clinically preferred [15]. In the present study, solitary metastatic bone cancer of the limbs was treated according to the principles for the treatment of primary bone cancer. En bloc resection was performed, followed by limb-salvage reconstruction of bone defects and limb function. To analyze the effectiveness of this strategy, the pain, QOL, limb function, tumor-free survival and operative complications were evaluated.

Material and Methods

GENERAL DATA:

From 2007 to 2010, a total of 27 patients with solitary metastatic bone cancer were treated in our department, including 15 males and 12 females, with a mean age of 58±8.58 years (range: 43–75 years). Follow-up was carried out for 16.15±7.47 months (range: 6–31) (t=1.073, P=0.294). The primary cancers included lung cancer in 7 patients, renal carcinoma in 6, breast cancer in 5, prostate cancer in 2, endometrial carcinoma in 1, thyroid cancer in 1, colon cancer in 1, rectal cancer in 1, liver cancer in 1, glioma in 1, and gastric cancer in 1 patient. Metastatic bone cancer was detected 8~123 months (mean: 42.20±33.61 months) after diagnosis of primary cancers in 20 patients, but metastatic bone cancer as the first sign facilitating the diagnosis of primary cancers was detected in 7 patients. The cancer metastasis sites included the proximal end of the femur in 11 patients, proximal end of the humerus in 6, middle part of the humerus in 3, scapula in 2, middle part of the femur in 2, distal end of the femur in 1, middle part of the ulna in 1, and proximal end of the tibia in 1 patient. The complaints included simple pain in 10 patients, pain and bump in 6, and pathological fracture in 7 patients. Four patients had no complaints and metastatic bone cancer was identified by routine ECT or PET. All data are shown in Table 1.

SURGICAL PROCEDURES:

Limb-salvage surgery was performed in all patients according to the principles for the treatment of primary bone cancer. Artificial prosthetic replacement was performed in 21 patients, simple resection in 2, reconstruction with allogeneic bones in 2, inactivated bone replantation in 1, and removal of hemi-cortex of the bone, filling of bone cerement, and internal fixation in 1 patient. In 7 patients, primary cancer and metastatic bone cancer were identified simultaneously and then a one-stage operation was carried out for resection of primary cancer and metastatic cancer simultaneously. According to the Enneking’s Staging System, wide resection was done in 19 patients and marginal resection in 8 patients. In 21 patients, post-operative systemic chemotherapy and/or local radiotherapy were performed, of whom 7 patients receiving marginal resection underwent local radiotherapy post-operatively. Six patients received surgical intervention alone and no adjunctive therapy was carried out.

POST-OPERATIVE EVALUATION:

QOL and pain were evaluated before and after surgery in 21 patients. Pain was assessed with the 10-point scale before and 1 month after surgery. The QOL was assessed with the SF-36 scale [14] before and 3 months after surgery. Scoring was done by the same physician. Post-operative limb function was evaluated with the American Musculoskeletal Tumor Society (MSTS) system 3 months after surgery.

STATISTICAL ANALYSIS:

Statistical analysis was performed with SPSS version 14.0. Quantitative data with normal distribution were expressed as mean ± standard deviation to describe the central tendency or discrete tendency. The scores of pain, QOL, and limb function were compared with the t test. Long rank test was employed for survival analysis between groups. Tumor-free survival was defined as the time from the end of surgery to the presence of new lesions. A value of P<0.05 was considered statistically significant.

Results

POSTOPERATIVE COMPLICATIONS:

All procedures were performed successfully, and no patient died during the follow-up period. Superficial incision infection was found in 2 patients and resolved after debridement. Post-operative prosthesis dislocation occurred in 1 patient and closed reduction was successfully carried out. Deep venous thrombosis was found in 3 patients of whom inferior vena cava filter was placed in 2 and systemic anti-coagulation therapy done in 1 patient. Pulmonary infection was controlled following anti-infection therapy in 1 patient.

EVALUATION OF PAIN, QOL AND LIMB FUNCTION:

As shown in Table 2, the score of pain was 6.85±3.11 and 1.26±0.81 before and 1 month after surgery, respectively, indicating that the post-operative pain was markedly improved (t=9.978, P<0.001). The QOL score was 38.30±13.05 and 65.78±10.65 before and 3 months after surgery, respectively, revealing the quality of life was dramatically improved following surgery (t=−18.550, P<0.001). The post-operative score of limb function ranged from 17 to 30 (mean: 23±3) (t=−1.450, P=0.016). Activities of daily living recovered in all patients. For patients with metastatic bone cancer in lower limbs, they could walk with or without a walker.

LOCAL RECURRENCE:

Regarding cancer control, no local recurrence occurred in these 27 patients during the follow-up period. As shown in Figure 1, log rank testing revealed there was no significant difference in the tumor-free survival between patients receiving wide resection and marginal resection (χ2=0.121, P=0.728).

REPRESENTATIVE CASES:

Case 1: Male, 43 years old, lung cancer. He was admitted due to pain and presence of pain and bump at the right hip for 2 months. On examination, a mass was found in the right lung and subsequent pathological examination revealed lung cancer. Radical resection for lung cancer and marginal resection of the bone cancer were performed (Figure 2).

Case 2: Male, 56 years old, prostate cancer concomitant with pathological fracture at proximal end of bilateral femurs. En bloc resection of the bone cancer and bilateral prosthetic replacement were performed (Figure 3).

Case 4: Male, 45 years old, renal carcinoma. Pathological fracture at the left humerus was found and subsequent pathological examination confirmed renal carcinoma. Left radical nephrectomy and en bloc resection of cancer at the left humerus were performed, followed by artificial prosthetic replacement (Figure 4).

Case 17: Male, 62 year old, swelling and pain at left forearm 2 years after resection of rectal cancer. Implantation of inactivated bone and internal fixation with plates were performed after marginal resection of the bone cancer (Figure 5).

Discussion

The bone is the third most common site of cancer metastasis, following lung and liver. In addition to the limbs, the spine is also a common site of cancer metastasis [3,16]. In the present study, we primarily focus on the surgical treatment of metastatic bone cancer of the limbs. Comprehensive therapy is preferred for the metastatic bone cancer, including surgical intervention, chemotherapy, radiotherapy and other conservative therapies [7,8,17]. Metastatic bone cancer is a systemic disease, thus surgical therapy is usually performed on the basis of other adjunctive therapies.

The majority of metastatic bone cancers are predominantly derived from lung cancer and breast cancer, followed by renal carcinoma, thyroid cancer and prostate cancer [18–20]. Metastatic bone cancer from lung cancer/renal carcinoma is usually characterized by osteolytic lesions [19], thus patients with this disease are susceptible to pathological fracture, and surgical intervention is required. Metastatic bone cancer from breast cancer/prostate cancer is usually osteogenic, especially in patients with prostate cancer [20]. When compared to patients with osteolytic lesions, those with osteogenic lesions seldom develop pathological fracture; conservative therapy is often performed and surgical intervention less often required [20,21].

In the present study, 1 patient with prostate cancer developed metastatic bone cancer and subsequent pathological fracture at the proximal end of bilateral femurs. Thus, for metastatic bone cancer patients with osteogenic lesions, the risk for pathological fracture should also be paid attention to, especially in those with intertrochanteric lesions. Mirels score is an important tool for the evaluation of risk for pathological fracture [22]. Patients with a Mirels score of ≥9 are regarded to have high risk for fracture, and active prophylactic surgery is required. For patients developing pathological fracture, determination of surgical intervention is done based on the general conditions: tolerance to surgery, time from identification of primary disease to metastatic bone cancer, disease progression, expected survival time, extent of post-operative QOL improvement, and post-operative limb function [5,16,21]. Generally, surgical intervention should be considered for patients with favorable general condition, able to tolerate surgery, having no progression of primary disease, with expected survival time of longer than 6 months, and having poor QOL due to pathological fracture [23,24]. Once surgical intervention is determined for the treatment of pathological fracture, the requirements are similar to those in the treatment of primary bone cancer. Wide or marginal resection is needed to reconstruct limb function [25]. The reconstruction should be beneficial for the rapid recovery of limb function or partial load-bearing. Usually, artificial prosthetic replacement is performed in patients with lesions near the joint; implantation of allogeneic bone or inactivated cancer-bearing bone, followed by internal fixation with plates, is recommended for patients with lesions at the bone shaft or non-weight-bearing site. In the present study, lesions were mainly found at the site near the joint, and thus artificial prosthetic replacement was the major strategy for the treatment; the post-operative limb function was markedly improved.

For pathological fracture, surgical treatment aims to relieve the pain and improve the QOL and limb function [4,5,12]. In the present study, surgical intervention was performed in patients with solitary metastatic bone cancer. Results demonstrate that post-operative pain, QOL, and limb function were dramatically improved. However, for patients with multiple bone metastases, surgical intervention is unable to achieve wide resection or resection of foci, and is usually highly invasive. Under this condition, patients usually have high surgical risk. Moreover, these patients have poor prognosis. Thus, selection of surgical intervention should be cautious [26,27].

In the present study, wide resection was performed in the majority of patients and a minority of patients received marginal resection. Post-operative local radiotherapy was also carried out as an adjunctive therapy, achieving favorable control of local tumors. No patients developed local recurrence during the follow-up period. In addition, statistical analysis showed there was no significant difference in the tumor-free survival time between patients receiving wide vs. marginal resection. This demonstrates that only systemic treatment is an effective strategy to improve the survival of cancer patients. Nevertheless, the wide or marginal resection of the cancer plays an important role in the control of local cancer and pain, and improvement of QOL and limb function.

In our study, metastatic bone cancer was the first sign in 7 patients and further examinations identified primary diseases. Of these patients, 6 received 1-stage resection of primary cancer and metastatic bone cancer simultaneously. The remaining patient had prostate cancer and pathological fracture at the proximal end of the bilateral femurs. Bilateral lesions were resectable and treatment was similar to that in patients with solitary metastatic bone cancer. One-stage resection of lesions at bilateral femurs was performed, followed by joint replacement, and endocrine therapy was done as a treatment for primary prostate cancer. For patients with resectable primary and metastatic lesions, post-operative chemotherapy and/or radiotherapy is recommended, which may significantly delay disease progression in the tumor-free survival time, elevate survival rate and improve QOL. This should be done in the presence of completely resectable primary and metastatic lesions. For these patients, resection of a single lesion may pronouncedly affect the effectiveness of adjunctive therapy and survival of cancer-bearing patients.

Conclusions

For patients with solitary metastatic bone cancer of the limbs, limb salvage surgery with wide or marginal resection is beneficial for the improvement of post-operative pain, QOL and limb function. In addition, the control of local cancer is also favorable and the local recurrence rate not influenced. For patients with metastatic bone cancer with concomitant primary cancer, 1-stage resection of both lesions is recommended, which may delay disease progression and improve the survival rate. In our study, the time of follow-up was relatively short, and the effect of limb salvage surgery on the overall survival needs to be further investigated in studies with long-term follow-up.

References

1. Coleman RE, Metastatic bone disease: clinical features, pathophysiology and treatment strategies: Cancer Treat Rev, 2001; 27; 165-76, pmid: 11417967

2. Papagelopoulos PJ, Savvidou OD, Galanis EC, Advances and challenges in diagnosis and management of skeletal metastases: Orthopedics, 2006; 29; 609-20, pmid: 16866093

3. Hage WD, Aboulafia AJ, Aboulafia DM, Incidence, location, and diagnostic evaluation of metastatic bone disease: Orthop Clin North Am, 2000; 31; 515-28, pmid: 11043092

4. Clohisy DR, Manthy PW, Bone cancer pain: Cancer, 2003; 97; 866-87, pmid: 12548588

5. Broos PLO, Rommens PM, Vanlangenaker MJU, Pathological fractures of the femur: improvement of quality of life after surgical treatment: Arch Orthop Trauma Surg, 1992; 111; 73-77, pmid: 1562428

6. Zhao H, Han KL, Wang ZY, Value of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors: Med Sci Monit, 2011; 17(11); CR626-33, pmid: 22037741

7. Janjan N, Bone metastases: approaches to management: Semin Oncol, 2001; 28; 28-34, pmid: 11544573

8. Weber KL, Lewis VO, Randall RL, An approach to the management of the patient with metastatic bone disease: Instr Course Lect, 2004; 53; 663-76, pmid: 15116657

9. Sharma H, Bhagat S, McCaul J, Intramedullary nailing for pathologyical femoral fractures: J Orthop Surg, 2007; 15(3); 291-94

10. Ward WG, Holsenbeck S, Dorey FJ, Metastatic disease of the femur: surgical treatment: Clin Orthop Relat Res, 2003(415 Suppl); S230-44, pmid: 14600615

11. Kim JH, Kang HG, Kim JR, Minimally invasive surgery of humeral metastasis using flexible nails and cement in high-risk patients with advanced cancer: Surg Oncol, 2011; 20(1); e32-37, pmid: 20870403

12. Talbot M, Turcotte RE, Isler M, Function and health status in surgically treated bone metastases: Clin Orthop Rel Res, 2005; 438; 215-20

13. Wai EK, Finkelstein JA, Tangente RP, Quality of life in surgical treatment of metastatic spine disease: Spine, 2003; 28; 508-12, pmid: 12616166

14. Reulen RC, Zeegers MP, Jenkinson C, The use of the SF-36 questionnaire in adult survivors of childhood cancer: evaluation of data quality, score reliability, and scaling assumptions: Health Qual Life Outcomes, 2006; 4; 77, pmid: 17022814

15. Sabo D, Bernd L, Surgical management of skeletal metastases of the extremities: Orthopade, 1998; 27(5); 274-81, pmid: 9646318

16. Dijkstra S, Wiggers T, Geel BTV, Boxma H, Impending and actual pathological fractures in patients with bone metastases of long bones: Eur J Surg, 1994; 160; 535-42, pmid: 7849154

17. Piccioli A, Ventura A, Maccauro G, Local adjuvants in surgical management of bone metastases: Int J Immunopathol Pharmacol, 2011; 24(1 Suppl 2); 129-32, pmid: 21669151

18. Coleman RE, Skeletal complications of malignancy: Cancer, 1997; 80; 1588-94, pmid: 9362426

19. Yuasa T, Urakami S, Yamamoto S, Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis: Clin Exp Metastasis, 2011; 28(4); 405-11, pmid: 21365325

20. Carlin BI, Andriole GL, The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma: Cancer, 2000; 88; 2989-94, pmid: 10898342

21. Hipp JA, Springfield DS, Hayes WC, Predicting pathologic fracture risk in the management of metastatic bone defects: Clin Orthop Relat Res, 1995; 312; 120-35, pmid: 7634597

22. Mirels H, Metastasis disease in long bones: A proposed scoring system for diagnosis impending pathologic fractures: Clin Orthop Relat Res, 2003; 415(Suppl); S4-S13, pmid: 14600587

23. Manabe J, Kawaguchi N, Matsumoto S, Tanizawa T, Surgical treatment of bone metastasis: indications and outcomes: Int J Clin Oncol, 2005; 10(2); 103-11, pmid: 15864695

24. Weber KL, Randall RL, Grossman S, Parvizi J, Management of lower-extremity bone metastasis: J Bone Joint Surg, 2006; 88; 11-19, pmid: 17142431

25. Zhang ZY, Fu CF, Yang YX, Long-term outcomes following en bloc resection for sacral tumor: a retrospective analysis of 93 cases: Orthopedics, 2011; 34(8); e403-7, pmid: 21815584

26. Bauer HC, Controversies in the surgical management of skeletal metastases: J Bone Joint Surg Br, 2005; 87; 608-17, pmid: 15855359

27. Healey JH, Brown HK, Complications of bone metastases: surgical management: Cancer, 2000; 88; 2940-51, pmid: 10898338

In Press

Clinical Research  

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...

Med Sci Monit In Press; DOI: 10.12659/MSM.951027  

Clinical Research  

Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...

Med Sci Monit In Press; DOI: 10.12659/MSM.950516  

Review article  

Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A Review

Med Sci Monit In Press; DOI: 10.12659/MSM.951283  

Clinical Research  

Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 Adults

Med Sci Monit In Press; DOI: 10.12659/MSM.950938  

Most Viewed Current Articles

17 Jan 2024 : Review article   10,187,196

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

13 Nov 2021 : Clinical Research   3,708,487

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

0:00

14 Dec 2022 : Clinical Research   2,341,643

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   706,524

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750